Engineering HIV-Resistant Human CD4+ T Cells with CXCR4-Specific Zinc-Finger Nucleases

English version České info

HIV-1 entry requires the cell surface expression of CD4 and either the CCR5 or CXCR4 coreceptors on host cells. Individuals homozygous for the ccr5Δ32 polymorphism do not express CCR5 and are protected from infection by CCR5-tropic (R5) virus strains. As an approach to inactivating CCR5, we introduced CCR5-specific zinc-finger nucleases into human CD4+ T cells prior to adoptive transfer, but the need to protect cells from virus strains that use CXCR4 (X4) in place of or in addition to CCR5 (R5X4) remains. Here we describe engineering a pair of zinc finger nucleases that, when introduced into human T cells, efficiently disrupt cxcr4 by cleavage and error-prone non-homologous DNA end-joining. The resulting cells proliferated normally and were resistant to infection by X4-tropic HIV-1 strains. CXCR4 could also be inactivated in ccr5Δ32 CD4+ T cells, and we show that such cells were resistant to all strains of HIV-1 tested. Loss of CXCR4 also provided protection from X4 HIV-1 in a humanized mouse model, though this protection was lost over time due to the emergence of R5-tropic viral mutants. These data suggest that CXCR4-specific ZFNs may prove useful in establishing resistance to CXCR4-tropic HIV for autologous transplant in HIV-infected individuals.

Vyšlo v časopise: Engineering HIV-Resistant Human CD4+ T Cells with CXCR4-Specific Zinc-Finger Nucleases. PLoS Pathog 7(4): e32767. doi:10.1371/journal.ppat.1002020
Kategorie: Research Article
prolekare.web.journal.doi_sk: https://doi.org/10.1371/journal.ppat.1002020

Souhrn

Zdroje

1. TiltonJCDomsRW 2010 Entry inhibitors in the treatment of HIV-1 infection. Antiviral Res 85 91 100

2. LiuRPaxtonWAChoeSCeradiniDMartinSR 1996 Homozygous defect in HIV-1 coreceptor accounts for resistance of some multiply-exposed individuals to HIV-1 infection. Cell 86 367 77

3. SamsonMLibertFDoranzBJRuckerJLiesnardC 1996 Resistance to HIV-1 infection in caucasian individuals bearing mutant alleles of the CCR-5 chemokine receptor gene. Nature 382 722 5

4. DeanMCarringtonMWinklerCHuttleyGASmithMW 1996 Genetic restriction of HIV-1 infection and progression to AIDS by a deletion allele of the CKR5 structural gene. Hemophilia Growth and Development Study, Multicenter AIDS Cohort Study, Multicenter Hemophilia Cohort Study, San Francisco City Cohort, ALIVE Study. Science 273 1856 62

5. HuangYPaxtonWAWolinskySMNeumannAUZhangL 1996 The role of a mutant CCR5 allele in HIV-1 transmission and disease progression. Nat Med 2 1240 3

6. HutterGNowakDMossnerMGanepolaSMussigA 2009 Long-term control of HIV by CCR5 Delta32/Delta32 stem-cell transplantation. N Engl J Med 360 692 8

7. ScarlattiGTresoldiEBjorndalAFredrikssonRColognesiC 1997 In vivo evolution of HIV-1 co-receptor usage and sensitivity to chemokine-mediated suppression. Nat Med 3 1259 65

8. ConnorRISheridanKECeradiniDChoeSLandauNR 1997 Change in coreceptor use correlates with disease progression in HIV-1–infected individuals. J Exp Med 185 621 8

9. WestbyMLewisMWhitcombJYouleMPozniakAL 2006 Emergence of CXCR4-using human immunodeficiency virus type 1 (HIV-1) variants in a minority of HIV-1-infected patients following treatment with the CCR5 antagonist maraviroc is from a pretreatment CXCR4-using virus reservoir. J Virol 80 4909 20

10. HendrixCWFlexnerCMacFarlandRTGiandomenicoCFuchsEJ 2000 Pharmacokinetics and safety of AMD-3100, a novel antagonist of the CXCR-4 chemokine receptor, in human volunteers. Antimicrob Agents Chemother 44 1667 73

11. HendrixCWCollierACLedermanMMScholsDPollardRB 2004 Safety, pharmacokinetics, and antiviral activity of AMD3100, a selective CXCR4 receptor inhibitor, in HIV-1 infection. J Acquir Immune Defic Syndr 37 1253 62

12. TiltonJCWilenCBDidiguCASinhaRHarrisonJE 2010 A maraviroc-resistant HIV-1 with narrow cross-resistance to other CCR5 antagonists depends on both N-terminal and extracellular loop domains of drug-bound CCR5. J Virol 84 10863 76

13. TiltonJCAmrine-MadsenHMiamidianJLKitrinosKMPfaffJ 2010 HIV type 1 from a patient with baseline resistance to CCR5 antagonists uses drug-bound receptor for entry. AIDS Res Hum Retroviruses 26 13 24

14. WestbyMSmith-BurchnellCMoriJLewisMMosleyM 2007 Reduced maximal inhibition in phenotypic susceptibility assays indicates that viral strains resistant to the CCR5 antagonist maraviroc utilize inhibitor-bound receptor for entry. J Virol 81 2359 71

15. OgertRAWojcikLBuontempoCBaLBuontempoP 2008 Mapping resistance to the CCR5 co-receptor antagonist vicriviroc using heterologous chimeric HIV-1 envelope genes reveals key determinants in the C2-V5 domain of gp120. Virology 373 387 99

16. TsibrisAMSagarMGulickRMSuZHughesM 2008 In vivo emergence of vicriviroc resistance in a human immunodeficiency virus type 1 subtype C-infected subject. J Virol 82 8210 4

17. BaiJGorantlaSBandaNCagnonLRossiJ 2000 Characterization of anti-CCR5 ribozyme-transduced CD34+ hematopoietic progenitor cells in vitro and in a SCID-hu mouse model in vivo. Mol Ther 1 244 54

18. DiGiustoDLKrishnanALiLLiHLiS 2010 RNA-based gene therapy for HIV with lentiviral vector-modified CD34(+) cells in patients undergoing transplantation for AIDS-related lymphoma. Sci Transl Med 2 36ra43

19. SwanCHBuhlerBSteinbergerPTschanMPBarbasCF 2006 T-cell protection and enrichment through lentiviral CCR5 intrabody gene delivery. Gene Ther 13 1480 92

20. Luis AbadJGonzalezMAdel RealGMiraEManesS 2003 Novel interfering bifunctional molecules against the CCR5 coreceptor are efficient inhibitors of HIV-1 infection. Mol Ther 8 475 84

21. AndersonJBanerjeaAAkkinaR 2003 Bispecific short hairpin siRNA constructs targeted to CD4, CXCR4, and CCR5 confer HIV-1 resistance. Oligonucleotides 13 303 12

22. AndersonJBanerjeaAPlanellesVAkkinaR 2003 Potent suppression of HIV type 1 infection by a short hairpin anti-CXCR4 siRNA. AIDS Res Hum Retroviruses 19 699 706

23. PerezEEWangJMillerJCJouvenotYKimKA 2008 Establishment of HIV-1 resistance in CD4+ T cells by genome editing using zinc-finger nucleases. Nat Biotechnol 26 808 16

24. ManiMKandavelouKDyFJDuraiSChandrasegaranS 2005 Design, engineering, and characterization of zinc finger nucleases. Biochem Biophys Res Commun 335 447 57

25. MillerJCHolmesMCWangJGuschinDYLeeYL 2007 An improved zinc-finger nuclease architecture for highly specific genome editing. Nat Biotechnol 25 778 85

26. PodhajskaAJSzybalskiW 1985 Conversion of the FokI endonuclease to a universal restriction enzyme: cleavage of phage M13mp7 DNA at predetermined sites. Gene 40 175 82

27. DuraiSManiMKandavelouKWuJPorteusMH 2005 Zinc finger nucleases: custom-designed molecular scissors for genome engineering of plant and mammalian cells. Nucleic Acids Res 33 5978 90

28. HoltNWangJKimKFriedmanGWangX 2010 Human hematopoietic stem/progenitor cells modified by zinc-finger nucleases targeted to CCR5 control HIV-1 in vivo. Nat Biotechnol 28 839 47

29. UrnovFDMillerJCLeeYLBeausejourCMRockJM 2005 Highly efficient endogenous human gene correction using designed zinc-finger nucleases. Nature 435 646 51

30. IsalanMChooY 2001 Rapid, high-throughput engineering of sequence-specific zinc finger DNA-binding proteins. Methods Enzymol 340 593 609

31. JamiesonACMillerJCPaboCO 2003 Drug discovery with engineered zinc-finger proteins. Nat Rev Drug Discov 2 361 8

32. IsalanMKlugAChooY 2001 A rapid, generally applicable method to engineer zinc fingers illustrated by targeting the HIV-1 promoter. Nat Biotechnol 19 656 60

33. NilssonMLjungbergJRichterJKieferTMagnussonM 2004 Development of an adenoviral vector system with adenovirus serotype 35 tropism; efficient transient gene transfer into primary malignant hematopoietic cells. J Gene Med 6 631 41

34. LevineBLMoscaJDRileyJLCarrollRGVaheyMT 1996 Antiviral effect and ex vivo CD4+ T cell proliferation in HIV-positive patients as a result of CD28 costimulation. Science 272 1939 43

35. OnlamoonNHudsonKBryanPMayneAEBonyhadiM 2006 Optimization of in vitro expansion of macaque CD4 T cells using anti-CD3 and co-stimulation for autotransfusion therapy. J Med Primatol 35 178 93

36. OnlamoonNPlagmanNRogersKAMayneAEBostikP 2007 Anti-CD3/28 mediated expansion of macaque CD4+ T cells is polyclonal and provides extended survival after adoptive transfer. J Med Primatol 36 206 18

37. BrelotAHevekerNAdemaKHosieMJWillettB 1999 Effect of mutations in the second extracellular loop of CXCR4 on its utilization by human and feline immunodeficiency viruses. J Virol 73 2576 86

38. LuZBersonJFChenYTurnerJDZhangT 1997 Evolution of HIV-1 coreceptor usage through interactions with distinct CCR5 and CXCR4 domains. Proc Natl Acad Sci U S A 94 6426 31

39. LeonRPHedlundTMeechSJLiSSchaackJ 1998 Adenoviral-mediated gene transfer in lymphocytes. Proc Natl Acad Sci USA 95 13159 64

40. DoyonYMcCammonJMMillerJCFarajiFNgoC 2008 Heritable targeted gene disruption in zebrafish using designed zinc-finger nucleases. Nat Biotechnol 26 702 8

41. LloydAPlaisierCLCarrollDDrewsGN 2005 Targeted mutagenesis using zinc-finger nucleases in Arabidopsis. Proc Natl Acad Sci USA 102 2232 7

42. BrelotAHevekerNPleskoffOSolNAlizonM 1997 Role of the first and third extracellular domains of CXCR-4 in human immunodeficiency virus coreceptor activity. J Virol 71 4744 51

43. RouletEBussoSCamargoAASimpsonAJMermodN 2002 High-throughput SELEX SAGE method for quantitative modeling of transcription-factor binding sites. Nat Biotechnol 20 831 5

44. FamulokMHuttenhoferA 1996 In vitro selection analysis of neomycin binding RNAs with a mutagenized pool of variants of the 16S rRNA decoding region. Biochemistry 35 4265 70

45. MoralesJAl-SharifLKhalilDSShinwariJMBaviP 2009 Homozygous mutations in ADAMTS10 and ADAMTS17 cause lenticular myopia, ectopia lentis, glaucoma, spherophakia, and short stature. Am J Hum Genet 85 558 68

46. LeungACWongVCYangLCChanPLDaigoY 2008 Frequent decreased expression of candidate tumor suppressor gene, DEC1, and its anchorage-independent growth properties and impact on global gene expression in esophageal carcinoma. Int J Cancer 122 587 94

47. CarrollRGRileyJLLevineBLFengYKaushalS 1997 Differential regulation of HIV-1 fusion cofactor expression by CD28 costimulation of CD4+ T cells. Science 276 273 6

48. HartleyOKlassePJSattentauQJMooreJP 2005 V3: HIV's switch-hitter. AIDS Res Hum Retroviruses 21 171 89

49. WilkTPfeifferTBoschV 1992 Retained in vitro infectivity and cytopathogenicity of HIV-1 despite truncation of the C-terminal tail of the env gene product. Virology 189 167 77

50. HarrisonJELynchJBSierraLJBlackburnLARayN 2008 Baseline resistance of primary human immunodeficiency virus type 1 strains to the CXCR4 inhibitor AMD3100. J Virol 82 11695 704

51. NagasawaTHirotaSTachibanaKTakakuraNNishikawaS 1996 Defects of B-cell lymphopoiesis and bone-marrow myelopoiesis in mice lacking the CXC chemokine PBSF/SDF-1. Nature 382 635 8

52. BleulCCFuhlbriggeRCCasasnovasJMAiutiASpringerTA 1996 A highly efficacious lymphocyte chemoattractant, stromal cell-derived factor 1 (SDF-1). J Exp Med 184 1101 9

53. BraveMFarrellAChing LinSOcheltreeTPope MiksinskiS 2010 FDA review summary: Mozobil in combination with granulocyte colony-stimulating factor to mobilize hematopoietic stem cells to the peripheral blood for collection and subsequent autologous transplantation. Oncology 78 282 8

54. NewrzelaSCornilsKLiZBaumCBrugmanMH 2008 Resistance of mature T cells to oncogene transformation. Blood 112 2278 86

55. JuneCHBlazarBRRileyJL 2009 Engineering lymphocyte subsets: tools, trials and tribulations. Nat Rev Immunol 9 704 16

56. Hacein-Bey-AbinaSHauerJLimAPicardCWangGP 2010 Efficacy of gene therapy for X-linked severe combined immunodeficiency. N Engl J Med 363 355 64

57. Cavazzana-CalvoMPayenENegreOWangGHehirK 2010 Transfusion independence and HMGA2 activation after gene therapy of human beta-thalassaemia. Nature 467 318 22

58. BoboilaCYanCWesemannDRJankovicMWangJH 2010 Alternative end-joining catalyzes class switch recombination in the absence of both Ku70 and DNA ligase 4. J Exp Med 207 417 27

59. WilkinTJSuZKuritzkesDRHughesMFlexnerC 2007 HIV type 1 chemokine coreceptor use among antiretroviral-experienced patients screened for a clinical trial of a CCR5 inhibitor: AIDS Clinical Trial Group A5211. Clin Infect Dis 44 591 5

60. HoxieJALaBrancheCCEndresMJTurnerJDBersonJF 1998 CD4-independent utilization of the CXCR4 chemokine receptor by HIV-1 and HIV-2. J Reprod Immunol 41 197 211

61. EsteJACabreraCBlancoJGutierrezABridgerG 1999 Shift of clinical human immunodeficiency virus type 1 isolates from X4 to R5 and prevention of emergence of the syncytium-inducing phenotype by blockade of CXCR4. J Virol 73 5577 85

62. PhilpottSWeiserBAnastosKKitchenCMRobisonE 2001 Preferential suppression of CXCR4-specific strains of HIV-1 by antiviral therapy. J Clin Invest 107 431 8